FDA delays approval for BMS cancer therapy
Bristol-Myers said the marketing application submitted to the U.S. FDA for its Opdivo plus Yervoy cancer therapy combination will be delayed by three months, until May 2019. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 22, 2018 Category: Pharmaceuticals Source Type: news
Immunotherapy may become new first line treatment in some metastatic colorectal cancers
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. (1) The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer. (Source: World Pharma News)
Source: World Pharma News - October 22, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Major response to immunotherapy in early-stage mismatch repair deficient colon cancer
(European Society for Medical Oncology) Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100 percent of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news
Immunotherapy may become new first line treatment in some metastatic colorectal cancers
(European Society for Medical Oncology) Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news
Machine-learning driven findings uncover new cellular players in tumor microenvironment
(CytoReason) New findings presented today by CytoReason reveals possible new cellular players in the tumor microenvironment that could impact the treatment process for the most in-need patients -- those who have already failed to respond to ipilimumab (anti-CTLA4) immunotherapy. Once validated, the findings could point the way to improved strategies for the staging and ordering of key immunotherapies in refractory melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2018 Category: International Medicine & Public Health Source Type: news
Nivolumab vs Ipilimumab in Treatment of Advanced Melanoma Nivolumab vs Ipilimumab in Treatment of Advanced Melanoma
A new study compares nivolumab in combination with ipilimumab or nivolumab vs. ipilimumab monotherapy for extending overall or progression-free survival in adults with advanced melanoma.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma
(MedPage Today) -- Good survival outcomes, but high rates of toxicities, with ipilimumab-nivolumab combo (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 12, 2018 Category: Dermatology Source Type: news
CTLA4 targeted therapy plus PD-1 targeted therapy could benefit women with ovarian cancer
(NRG Oncology) An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer. These results were presented as a late-breaking abstract oral presentation at the 17th Biennial Meeting of the International Gynecological Cancer Society (IGCS) in Kyoto, Japan. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 19, 2018 Category: Cancer & Oncology Source Type: news
Surgery for Mesothelioma No Longer Recommended in UK
Aggressive surgery for the treatment of malignant pleural mesothelioma (MPM) — unless part of a clinical trial — is no longer being recommended in the United Kingdom.
The British Thoracic Society recently published its Mesothelioma Management Guidelines for 2018 and removed surgery from its recommendations. The belief was that potential harm was not worth the risk.
The backtrack on surgery included the extrapleural pneumonectomy (EPP), the extended pleurectomy and decortication (P/D) and the partial pleurectomy (PP) — all of which are being done at cancer centers in the United States.
“Surgery is a controversial ar...
Source: Asbestos and Mesothelioma News - September 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
Drug Combo, Opdivo and Yervoy, Fights Melanoma That Has Spread to Brain
THURSDAY, Aug. 23, 2018 -- A combination of two drugs that work with the immune system can help beat back melanoma that has moved to the brain, an early clinical trial has found.
The study included 94 patients with advanced melanoma that had... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 23, 2018 Category: General Medicine Source Type: news
Dual Immunotherapy a Winner for Melanoma Brain Mets Dual Immunotherapy a Winner for Melanoma Brain Mets
A combination of two checkpoint inhibitors (nivolumab and ipilimumab) achieved ' clinically meaningful ' efficacy in patients with asymptomatic, untreated melanoma metastases to the brain.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Nivolumab & #43; Ipilimumab Shows Efficacy for Untreated Brain Mets
WEDNESDAY, Aug. 22, 2018 -- For patients with melanoma and untreated brain metastases, nivolumab combined with ipilimumab shows clinically meaningful efficacy, according to a study published in the Aug. 23 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 22, 2018 Category: Pharmaceuticals Source Type: news
Bristol-Myers to get negative CHMP opinion on renal cancer drugs
Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
High-Dose Glucocorticoids for Hypophysitis Are Worse in Melanoma Patients
Melanoma patients who were treated with glucocorticoids for ipilimumab-induced hypophysitis had improved survival outcomes if they received low doses. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
BMS ’ Opdivo/Yervoy combo cleared for kidney cancer
Approval was based on data from the Phase III CheckMate -214 clinical trial, in which the Opdivo (nivolumab) + Yervoy (ipilimumab) combination showed “a significant and unprecedented increase in overall survival (OS) in this patient population compared to a current standard of care, sunitinib,” according to BMS.07/16/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 16, 2018 Category: Urology & Nephrology Source Type: news
